Literature DB >> 7614089

Machado-Joseph disease.

L Sudarsky1, P Coutinho.   

Abstract

Machado-Joseph disease (MJD) is a form of dominantly-inherited ataxia originally described in people of Azorean and Portuguese descent. The disorder has subsequently been identified in Japan, Brazil, Australia, and China. Average age of onset is 35 to 40. Core features include progressive ataxia, dysarthria, postural instability, nystagmus, eyelid retraction, and facial fasciculations. Dystonia is often prominent in younger patients. Three distinct phenotypes appear to reflect the clinical spectrum of a single mutant gene. Neuropathology involves afferent and efferent cerebellar systems, with preservation of cerebellar cortex and inferior olive. Spinocerebellar pathways, substantia nigra, and cranial nerve motor nuclei are involved. The disorder is due to an unstable CAG repeat on chromosome 14q32.1. A dominantly inherited ataxia (SCA-3) in families of French and German descent has also been linked to this segment of chromosome 14. The relationship between MJD and the other dominant inherited ataxias is discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7614089

Source DB:  PubMed          Journal:  Clin Neurosci        ISSN: 1065-6766


  22 in total

Review 1.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

Review 2.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

Review 3.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 4.  The inherited ataxias and the new genetics.

Authors:  S R Hammans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

5.  The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia.

Authors:  D H Geschwind; S Perlman; C P Figueroa; L J Treiman; S M Pulst
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

6.  PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Authors:  Na-Li Jia; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

7.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

8.  Aggregation of actin and cofilin in identical twins with juvenile-onset dystonia.

Authors:  Marla Gearing; Jorge L Juncos; Vincent Procaccio; Claire-Anne Gutekunst; Elaine M Marino-Rodriguez; Kymberly A Gyure; Shoichiro Ono; Robert Santoianni; Nicolas S Krawiecki; Douglas C Wallace; Bruce H Wainer
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

9.  Widespread neuronal damage and cognitive dysfunction in spinocerebellar ataxia type 3.

Authors:  Tátila Martins Lopes; Anelyssa D'Abreu; Marcondes Cavalcante França; Clarissa Lin Yasuda; Luiz Eduardo Betting; Adriana Bastos Samara; Gabriela Castellano; Júlio César Somazz; Marcio Luiz Figueredo Balthazar; Iscia Lopes-Cendes; Fernando Cendes
Journal:  J Neurol       Date:  2013-06-18       Impact factor: 4.849

10.  Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Adriana Marcelo; Teresa Pereira Silva; João Barata; Ana Vasconcelos-Ferreira; Dina Pereira; Clévio Nóbrega; Sónia Duarte; Inês Barros; Joana Alves; José Sereno; Lorena Itatí Petrella; João Castelhano; Vitor Hugo Paiva; Paulo Rodrigues-Santos; Vera Alves; Isabel Nunes-Correia; Rui Jorge Nobre; Célia Gomes; Miguel Castelo-Branco; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.